Coronavirus Infections

Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).

Also Known As:

Networked: 1279 relevant articles (72 outcomes, 179 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	COVID-19
2.	Severe Acute Respiratory Syndrome
3.	Infections
4.	Human Influenza (Influenza)
5.	Virus Diseases (Viral Diseases)

Experts

1.	Perlman, Stanley: 18 articles (01/2022 - 09/2005)
2.	Arabi, Yaseen M: 11 articles (11/2021 - 10/2017)
3.	Jose, Jesna: 10 articles (11/2021 - 10/2017)
4.	Hayden, Frederick G: 10 articles (10/2020 - 11/2013)
5.	Baric, Ralph S: 9 articles (01/2022 - 12/2014)
6.	Begrambekova, Yu L: 9 articles (12/2021 - 01/2020)
7.	Liu, Ding Xiang: 8 articles (12/2022 - 01/2008)
8.	Jiang, Shibo: 8 articles (01/2022 - 01/2015)
9.	Mareev, V Yu: 8 articles (12/2021 - 01/2020)
10.	Mareev, Yu V: 8 articles (12/2021 - 01/2020)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Coronavirus Infections:

1.	VaccinesIBA 01/01/2020 - "Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. " 01/01/2022 - "Animal models can reproduce the viral replication cycle and the significant functions of respiratory coronavirus infection and are urgently needed to evaluate the efficacy of drugs and vaccines, the transmission route of respiratory coronavirus, clinical features, and so on. " 07/01/2020 - "Currently there is no effective treatment for coronavirus infection; major effort is to develop vaccine against the virus and development of therapeutic drugs for the disease. " 01/01/2015 - "The outbreaks of Middle East respiratory syndrome (MERS) previously in Middle East and recently in South Korea have raised serious concerns worldwide, reinforcing the importance of developing effective and safe vaccines against MERS-coronavirus (MERS-CoV). " 12/15/2021 - "These findings provide the first demonstration to our knowledge that coronavirus vaccines (and prior coronavirus infections) can confer broad protection against heterologous coronaviruses and establish a rationale for universal coronavirus vaccines."
2.	Antiviral Agents (Antivirals)IBA 12/21/2022 - "We also demonstrated that IFN-λ3 induced greater antiviral activity against TGEV replication than did IFN-λ1 in IPEC-J2 cells, which is helpful in finding a novel strategy for the treatment of coronavirus infections." 05/01/2015 - "However, no studies have previously reported a structural platform for the design of antiviral drugs with activities against these viruses or on the efficacy of 3CLpro inhibitors against coronavirus infection in experimental animals. " 09/01/2023 - "Further studies of the intracellular mechanisms used by the virus to replicate could help to develop antiviral drugs for the treatment of the new coronavirus infection." 01/01/2023 - "Our study suggests that IRFs may be effective antiviral regulators against human coronavirus infection." 01/01/2023 - "It provides a better understanding of milk sEV resistance to coronavirus infection, warranting further studies to develop sEV as an attractive antiviral."
3.	GlucocorticoidsIBA 10/01/2022 - "We have also addressed the specific activation of the immune system with chronic endogenous glucocorticoid excess, as seen in patients with Cushing syndrome, and, finally, we have discussed immune activation due to coronavirus infection and the possible mechanisms leading to improved outcomes in patients with COVID-19 treated with GCs. " 05/01/2020 - "We included randomized controlled trials (RCTs) and cohort studies evaluating the effectiveness and safety of glucocorticoids in children and adults with COVID-19, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and conducted meta-analyses of the main indicators that were identified in the studies. " 12/01/2020 - "Meanwhile, like other coronavirus infections, COVID-19 leads to the cytokine storm syndrome resulting in hyperinflammation, exacerbated immune response and multiple organ dysfunctions indicating that drugs that modulate this response, as glucocorticoids could be a treatment option. " 06/17/2022 - "At the same time, the nosological form, the use of anti-rheumatic drugs and glucocorticoids did not increase the risks of severe coronavirus infection. " 01/01/2021 - "The finding that high-dose dexamethasone improves survival in those requiring critical care due to COVID-19 will mean much greater usage of glucocorticoids in the subsequent waves of coronavirus infection. "
4.	InterferonsIBA 11/01/1983 - "Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers." 01/01/2022 - "Analyses of patients have revealed marked dysregulation of the immune system in severe cases of human coronavirus infection, and there is ample evidence that aberrant immune responses to human coronaviruses are typified by impaired induction of interferons, exuberant inflammatory responses and delayed adaptive immune responses. " 01/01/2022 - "Here, using mice that are deficient in type I (IFNAR1-/-), type III (IFNLR1-/-), or both (IFNAR1/LR1-/-) interferon signaling pathways and murine-adapted coronavirus (MHV-A59) administered through the intranasal route, we define the role of interferons in coronavirus infection. " 11/15/2018 - "Coronavirus infection induces ER stress and the interferon response, which reflects different adaptive cellular processes. " 01/01/1983 - "Interferon induction in rotavirus and coronavirus infections: a review of recent results."
5.	LopinavirFDA Link 12/01/2020 - "Among the four tested compounds, lopinavir showed the best inhibitory effect against the novel coronavirus infection. " 01/03/2020 - "Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial." 01/30/2018 - "Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial." 06/30/2020 - "In this paper we review the studies evaluating lopinavir/ritonavir association (LPV/r) use in COVID-19, and previously in SARS and Middle East respiratory syndrome (MERS). " 02/01/2020 - "In view of the earlier evidence about effectiveness of repurposed lopinavir/ritonavir against severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronavirus (CoV), as well as preliminary docking studies conducted by the ICMR-National Institute of Virology, Pune, the Central Drugs Standard Control Organization approved the restricted public health use of lopinavir/ritonavir combination amongst symptomatic COVID-19 patients detected in the country. "
6.	Ritonavir (Norvir)FDA Link 01/03/2020 - "Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial." 01/30/2018 - "Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial." 06/30/2020 - "In this paper we review the studies evaluating lopinavir/ritonavir association (LPV/r) use in COVID-19, and previously in SARS and Middle East respiratory syndrome (MERS). " 02/01/2020 - "In view of the earlier evidence about effectiveness of repurposed lopinavir/ritonavir against severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronavirus (CoV), as well as preliminary docking studies conducted by the ICMR-National Institute of Virology, Pune, the Central Drugs Standard Control Organization approved the restricted public health use of lopinavir/ritonavir combination amongst symptomatic COVID-19 patients detected in the country. " 01/01/2020 - "Lopinavir/ritonavir has been used for the treatment of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) coronavirus infections. "
7.	remdesivirIBA 01/01/2023 - "Remdesivir possesses in vitro inhibitory effect against severe acute respiratory syndrome coronavirus 2 and the Middle East respiratory syndrome. " 01/01/2022 - "Further, SFN and remdesivir interacted synergistically to inhibit coronavirus infection in vitro. " 03/25/2021 - "Further, SFN and remdesivir interacted synergistically to inhibit coronavirus infection in vitro. " 09/01/2020 - "Coronaviruses have caused serious Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and Coronavirus Disease 2019 (COVID-19) outbreaks, and only remdesivir has been recently indicated for the treatment of COVID-19. " 01/01/2021 - "Moreover, our results suggest that stenoparib and remdesivir in combination may be especially potent against coronavirus infection."
8.	FlavonoidsIBA 01/01/2022 - "The novelty of the approach mainly rests in the identification of potent anti-viral natural molecules from natural products flavonoid group of molecules to be effective against the latest coronavirus infection.Communicated" 01/01/2021 - "Flavonoids and their derivatives may stand for target compounds to be tested in future clinical trials to enrich the drug arsenal against coronavirus infections. " 09/01/2020 - "Due to their pleiotropic activities and lack of systemic toxicity, flavonoids and their derivative may represent target compounds to be tested in future clinical trials to enrich the drug arsenal against coronavirus infections." 09/01/2020 - "Roles of flavonoids against coronavirus infection." 01/01/2021 - "Bioflavonoids are the largest group of plant-derived polyphenolic compounds with diverse biological potential and have also been proven efficacious in the treatment of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). "
9.	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 12/31/2020 - "Dose Optimization of Hydroxychloroquine for Coronavirus Infection 2019: Do Blood Concentrations Matter?" 07/01/2020 - "As of today, 3 April 2020, 972,640 people affected and 50,325 people died from Severe Acute Respiratory Syndrome-Coronavirus 2. There is not any standard treatment for coronavirus infection 2019; however, there are promising data for hydroxychloroquine and some anti-retroviral drugs. " 01/01/2020 - "60% of the technicians have received hydroxychloroquine as prophylaxis against coronavirus infection. " 03/02/2021 - "Hydroxychloroquine in patients with novel coronavirus infection (COVID-19): a case-control study." 01/01/2022 - "Prednisolone raised the coronavirus infection, and hydroxychloroquine played a protective role in the current study. "
10.	JIB-04IBA 01/01/2022 - "Furthermore, JIB-04 conferred protection in a porcine model of coronavirus infection, although to a lesser extent when given as therapeutic rather than prophylactic doses. " 01/01/2022 - "In an in vivo porcine model of coronavirus infection, administration of JIB-04 reduced virus infection and associated tissue pathology, which resulted in improved weight gain and survival. " 06/04/2021 - "In an in vivo porcine model of coronavirus infection, administration of JIB-04 reduced virus infection and associated tissue pathology, which resulted in improved weight gain and survival. "

Therapies and Procedures

1.	Therapeutics 08/13/2013 - "Additionally, since membrane rearrangement is a tactic used by all known positive-sense single-stranded RNA viruses, this work adds to that body of knowledge and may prove beneficial in the development of future therapies not only for human coronavirus infections but for other pathogens as well." 12/26/2022 - "A prospective, multicenter, comparative, randomized, double-blind, placebo-controlled study of the safety and efficacy of sequential therapy with Brainmax® enrolled 160 patients 12-16 weeks after coronavirus infection (no more than 12 months). " 01/01/2022 - "Overall, our results identify that ZBP1 induced during coronavirus infection limits the efficacy of IFN therapy by driving inflammatory cell death and lethality. " 06/01/2020 - "Available animal and cell line models have suggested that specific therapeutics might be effective in treating Middle East respiratory syndrome (MERS). " 01/01/2021 - "Despite promising results in the preclinical and clinical applications of MSC therapy for coronavirus infections, controversy still exists, and thus further investigation is required to understand the efficacy of these therapies."
2.	Mechanical Ventilators (Ventilator) 12/01/2023 - "There is strong observational evidence that respirators are highly effective in protecting the users from being infected with Middle East respiratory syndrome and severe acute respiratory syndrome coronavirus (SARS-CoV), but the evidence for SARS-CoV-2 during daily work is limited. " 10/31/2020 - "Surgical masks vs respirators for the protection against coronavirus infection: state of the art." 07/01/2020 - "There are few published data on the efficacy of masks or respirators against coronavirus infections. " 11/01/2020 - "In relation to face masks, the evidence indicates that a higher-level specification of face masks and respirators (such as N95) seems to be essential to protect HCWs from coronavirus infection. " 07/01/2020 - "These are the only available clinical trial data on coronavirus infections associated with mask or respirator use. "
3.	Cell- and Tissue-Based Therapy (Cell Therapy) 01/01/2023 - "We conducted a systematic review and meta-analysis of advanced cell therapy clinical trials as potential novel treatment for COVID-19 (resulting from SARS-CoV-2 coronavirus infection), including analysis of the global clinical trial landscape, published safety/efficacy outcomes (RR/OR), and details on cell product manufacturing and clinical delivery. "
4.	Length of Stay 12/12/2022 - "In South Korea, after the spread of the Middle East Respiratory Syndrome epidemic was aggravated by long stays in crowded emergency departments (EDs), a 24-hour target policy for EDs was introduced to prevent crowding and reduce patients' length of stay (LOS). " 03/01/2022 - "Owing to anti-epidemic measures, including the patient flow distribution, an introduction of mandatory testing, an early detection of patients and carriers among employees, mask regime, the opening of an observational department, single rooms, the lack of contact between patients, short length of stay, it was possible to prevent an outbreak of coronavirus infection among patients and personnel. " 03/01/2021 - "[Prevalence of SARS-CoV-2 coronavirus infection in patients and professional staff at a medium or long-stay hospital in Spain]." 08/14/2020 - "All patients who remained for at least one-day inpatient post-lung surgery were assessed to see if they had an increased incidence of coronavirus infection during the hospital stay or at the follow-up office visit. " 01/01/2020 - "The burn patients are usually debilitated and require a prolonged hospital stay and multiple operative procedures which put them and everyone involved in their care at increased risk of coronavirus infections and transmission. "
5.	Nebulizers and Vaporizers (Inhaler) 01/01/2021 - "Objectives: To assess the risk of transmitting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS, Middle East respiratory syndrome (MERS), and influenza with administration of drugs via nebulizer. " 01/01/2021 - "In this hypothesis, a novel combination strategy is introduced with the existing drugs such as hydroxychloroquine and flavonoid in a volatile liquid-based Nanoformulation incorporated into an inhaler as a possible remedy for the management of coronavirus infection. "